Bisphosphonates: Mechanism of Action and Role in Clinical Practice

Drake, Matthew T.; Clarke, Bart L.; Khosla, Sundeep
September 2008
Mayo Clinic Proceedings;Sep2008, Vol. 83 Issue 9, p1032
Academic Journal
Bisphosphonates are primary agents in the current pharmacological arsenal against osteoclast-mediated bone loss due to osteoporosis, Paget disease of bone, malignancies metastatic to bone, multiple myeloma, and hypercalcemia of malignancy. In addition to currently approved uses, bisphosphonates are commonly prescribed for prevention and treatment of a variety of other skeletal conditions, such as low bone density and osteogenesis imperfecta. However, the recent recognition that bisphosphonate use is associated with pathologic conditions including osteonecrosis of the jaw has sharpened the level of scrutiny of the current widespread use of bisphosphonate therapy. Using the key words bisphosphonate and clinical practice in a PubMed literature search from January 1, 1998, to May 1, 2008, we review current understanding of the mechanisms by which bisphosphonates exert their effects on osteoclasts, discuss the role of bisphosphonates in clinical practice, and highlight some areas of concern associated with bisphosphonate use.


Related Articles

  • Different theories on pathogenesis of bisphosphonate-related osteonecrosis of the jaw - A review. Dembowska, Elżbieta; Samulak-Zielińska, Renata; Sporniak-Tutak, Katarzyna // HealthMed;2014, Vol. 8 Issue 1, p140 

    Bisphosphonates (BPs) arc used to manage osteoporosis, Paget's disease, multiple myeloma, bone cancer and metastases, hypercalcemia of malignancy, fibrous dysplasia and chronic osteomyelitis. BPs reduce pain, pathological fractures, the size of osteolytic lesions and limit metastasis in certain...

  • BISPHOSPHONATES: CAN THESE BE THE BONE EATERS? Chhabra, Ajay; Chhabra, Vandana // Annals & Essences of Dentistry;Oct2011, Vol. 3 Issue 4, p94 

    Bisphosphonates are a group of synthetic analogs of inorganic pyrophosphate (an endogenous regulator of bone mineralization) Bisphosphonates are a family of druqs used to prevent and treat osteoporosis, multiple myeloma, Paget's disease (bone cancers), and bone metastasis from other cancers....

  • Clinical Application of Bisphosphonates in Implant Dentistry: Histomorphometric Evaluation. Zuffetti, Francesco; Bianchi, Francesca; Volpi, Raffaele; Trisi, Paolo; Fabbro, Massimo Del; Capelli, Matteo; Galli, Fabio; Capsoni, Franco; Testori, Tiziano // International Journal of Periodontics & Restorative Dentistry;2009, Vol. 29 Issue 1, p30 

    Bisphosphonates are pharmacologic compounds characterized by high tropism to bone tissue. They affect bone metabolism by inhibition of osteoclast recruitment, proliferation, differentiation, and function. Because they can reduce bone resorption, bisphosphonates are used mainly for the treatment...

  • Clinical use of bisphosphonates in the UK. Francis, RM // Journal of the British Menopause Society;2001, Vol. 7 Issue 2, p75 

    Bisphosphonates are synthetic analogues of naturally occurring pyrophosphate, but contain a P-C-P bond in the middle of the molecule instead of a P-O-P bond. The addition of different side chains allows many structural variations, producing bisphosphonates with a range of potencies and...

  • Risedronate: A Viewpoint by C. Conrad Johnston, Jr. Johnston, C.C.J. // Drugs & Aging;1998, Vol. 13 Issue 1, p92 

    Comments on the potential use of the biphosphonate risedronate in the treatment of Paget's disease of bone and osteoporosis. Physiological effects of risedronate; Absence of gastrointestinal adverse effects in risedronate-treated patients; Initial results of clinical trials on the use of...

  • Risedronate Sodium for the Treatment of Osteoporosis and Paget's Disease: The Evidence of its Therapeutic Value. Stanford, Phoebe E.; Center, Jacqueline R. // Clinical Medicine Reviews in Therapeutics;2012, Vol. 4, p109 

    Risedronate is a third generation bisphosphonate used in the prevention of osteoporotic fractures and the treatment of Paget's disease. In patients with osteoporosis, risedronate reduces bone turnover, improves bone density and reduces the risk of both vertebral and non-vertebral fractures....

  • The Second Most Common Bone Disease: A Review on Paget’s Disease of Bone. Seitz, Sebastian; Priemel, Matthias; von Domarus, Christoph; Beil, F. Timo; Barvencik, Florian; Amling, Michael; Rueger, Johannes M. // European Journal of Trauma & Emergency Surgery;Dec2008, Vol. 34 Issue 6, p549 

    Paget disease of bone (PDB) is the second most common metabolic bone disease. It is a chronic disease with a mono- or polyostotic appearance that is characterized by an increased bone turnover. The orthopedic surgeon is often confronted with such symptoms and complications as bone pain, skeletal...

  • Pharmacotherapy with Pamidronate Disodium of Osteolytic Bone Metastases of Breast Cancer, Osteolytic Lesions of Multiple Myeloma, and Paget's Disease. Hoff, Ana O.; Novis, Yana // Clinical Medicine: Therapeutics;2009, Issue 1, p953 

    High bone turnover disorders are characterized by excessive osteoclastic activity resulting in loss of bone mass and quality, fractures, deformities, debilitating pain, loss of mobility and hypercalcemia. These complications have a major impact in quality of life,and control of osteoclast...

  • The Buzz about Bisphosphonates: What the Dental Hygienist Needs to Know. Moore, Liz // Journal of the California Dental Hygienists' Association;Fall2006, Vol. 22 Issue 1, p19 

    The article provides information about biphosphonate drugs and the factors needed to be considered by dental hygienists in the U.S. with regard to its application. Several of the most familiar brands of biphosphonate drugs include Fosamax, Actonel, Boniva, Aredia or Zometa, used mainly in the...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics